Last reviewed · How we verify
Akynzeo solution
Akynzeo is a fixed-dose combination of netupitant (NK1 receptor antagonist) and palonosetron (5-HT3 receptor antagonist) that prevents chemotherapy-induced nausea and vomiting by blocking two key pathways in the chemoreceptor trigger zone and gastrointestinal tract.
Akynzeo is a fixed-dose combination of netupitant (NK1 receptor antagonist) and palonosetron (5-HT3 receptor antagonist) that prevents chemotherapy-induced nausea and vomiting by blocking two key pathways in the chemoreceptor trigger zone and gastrointestinal tract. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy, Prevention of CINV in patients receiving moderately emetogenic chemotherapy.
At a glance
| Generic name | Akynzeo solution |
|---|---|
| Also known as | IV Akynzeo®, Olanzapine |
| Sponsor | Helsinn Healthcare SA |
| Drug class | NK1 receptor antagonist / 5-HT3 receptor antagonist combination |
| Target | NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Netupitant blocks neurokinin-1 (NK1) receptors, which are involved in the central processing of emetic signals, particularly for delayed nausea and vomiting. Palonosetron blocks serotonin 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone, addressing acute nausea and vomiting. The dual mechanism provides comprehensive coverage across both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV).
Approved indications
- Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy
- Prevention of CINV in patients receiving moderately emetogenic chemotherapy
Common side effects
- Headache
- Constipation
- Fatigue
- Diarrhea
- Dyspepsia
Key clinical trials
- A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers (PHASE1)
- PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting (PHASE2)
- A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer (PHASE3)
- A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Akynzeo solution CI brief — competitive landscape report
- Akynzeo solution updates RSS · CI watch RSS
- Helsinn Healthcare SA portfolio CI